MarketPulse

pipeline

5 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Pharma Giants Poised for Growth: Lilly, Vertex, Pfizer Lead March 2026 Rally

Eli Lilly dominates weight management, Vertex controls cystic fibrosis, and Pfizer offers undervalued shares with 6.3% dividend yield.
PFELLYVRTXdividend yieldcystic fibrosis
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Plans First R&D Day to Showcase Pipeline, New Cell Therapy Tech

Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.
MESORyoncil®cellular medicines
BenzingaBenzinga··Prnewswire

Orexo Charts New Course with R&D Day Showcase of AmorphOX Pipeline

Orexo invites investors to March 24 R&D Day in Stockholm to present post-Zubsolv strategy, featuring AmorphOX technology and pipeline programs OX640 and OX390.
ORXOYpipelinestrategic priorities
BenzingaBenzinga··Vandana Singh

Merck Restructures Commercial Operations Ahead of Keytruda Patent Cliff

Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.
MRKrestructuringpatent expiration
The Motley FoolThe Motley Fool··Adria Cimino

Iovance Biotherapeutics Expands Market Presence Following Amtagvi Approval

Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.
IOVAbiotechclinical trials